

# Hydrogen Water and Eye Health

*Posted on December 9, 2019 by Rhona Reid*

Whether you're short-sighted, long-sighted or have perfect vision, we all want problem-free, functioning eyes. Did you know that Hydrogen Water helps our eyes to stay healthy? Keep reading below to learn how!



Hydrogen Water helps to keep your eyes healthy.

## Antioxidants and Eye Health

As with everything, eating right is a big factor when it comes to our eyes. Antioxidant-rich foods containing vitamin C are particularly good for our eye health.

Were you ever told as a kid that carrots help you to see in the dark? It seems that our grandmothers' saying is rooted in scientific fact!

Drinking freshly ionized Hydrogen Water directly from a special pouch takes things to another level.

It means that you're maximizing your intake of powerful, free radical-busting antioxidants and vital minerals with every pouch.

“Water treated by electrolysis to increase its reduction potential is the best solution to the problem of providing a safe source of free electrons to block the oxidation of normal tissue by free oxygen radicals.” – **Dr. Hidemitsu Hayashi, Director of the Water Institute of Japan**

## Can My Eyes Get Dehydrated?

Yes, they can!

Underpinning all aspects of robust good health is being properly hydrated, and your eyes need hydration just like every other part of your body.

Dehydration can be detrimental to eye health, which is why ultra-hydrating Hydrogen Water is so important.

# How Does Hydrogen Water Promote Eye Health?

It's not just about preventing damage to your eyes and keeping them healthy: Molecular Hydrogen can be used to actively heal and restore retinal health.

This clinical study published by the Association for Research in Vision and Ophthalmology concluded that Molecular Hydrogen dissolved in water was an effective treatment for a damaged retina.

“H<sub>2</sub> has no known toxic effects on the human body. Thus, the results suggest that H<sub>2</sub>-loaded eye drops are a highly useful neuroprotective and antioxidative therapeutic treatment for acute retinal I/R injury.” –

**Hideaki Oharazawa et al, Department of Ophthalmology, Nippon Medical School, Kanagawa, Japan**

**Retina January 2010**

## **Protection of the Retina by Rapid Diffusion of Hydrogen: Administration of Hydrogen-Loaded Eye Drops in Retinal Ischemia–Reperfusion Injury**

Hideaki Oharazawa; Tsutomu Igarashi; Takashi Yokota; Hiroaki Fujii; Hisaharu Suzuki; Mitsuru Machide; Hiroshi Takahashi; Shigeo Ohta; Ikuroh Ohsawa

Investigative Ophthalmology & Visual Science January 2010, Vol.51, 487-492.  
doi:<https://doi.org/10.1167/iovs.09-4089>

### **Abstract**

**Purpose:** Retinal ischemia-reperfusion (I/R) injury by transient elevation of intraocular pressure (IOP) is known to induce neuronal damage through the generation of reactive oxygen species. Study results have indicated that molecular hydrogen (H<sub>2</sub>) is an efficient antioxidant gas that selectively reduces the hydroxyl radical ( $\cdot$ OH) and suppresses oxidative stress-induced injury in several organs. This study was conducted to explore the neuroprotective effect of H<sub>2</sub>-loaded eye drops on retinal I/R injury.

**Methods:** Retinal ischemia was induced in rats by raising IOP for 60 minutes. H<sub>2</sub>-loaded eye drops were prepared by dissolving H<sub>2</sub> gas into a saline to saturated level and administered to the ocular surface continuously during the ischemia and/or reperfusion periods. One day after I/R injury, apoptotic cells in the retina were quantified, and oxidative stress was evaluated by markers such as 4-hydroxynonenal and 8-hydroxy-2-deoxyguanosine. Seven days after I/R injury, retinal damage was quantified by measuring the thickness of the retina.

**Results:** When H<sub>2</sub>-loaded eye drops were continuously administered, H<sub>2</sub> concentration in the vitreous body immediately increased and I/R-induced OH level decreased. The drops reduced the number of retinal apoptotic and oxidative stress marker–positive cells and prevented retinal thinning with an accompanying activation of Müller glia, astrocytes, and microglia. The drops improved the recovery of retinal thickness by >70%.

**Conclusions:** H<sub>2</sub> has no known toxic effects on the human body. Thus, the results suggest that H<sub>2</sub>-loaded eye drops are a highly useful neuroprotective and antioxidative therapeutic treatment for acute retinal I/R injury.

Retinal ischemia-reperfusion (I/R) injury by transient elevation of intraocular pressure (IOP) in animal models is known to induce necrosis and apoptosis of cells and significant reductions in thickness in multiple layers of the retina.<sup>1,2</sup> Clinically, these features closely resemble several diseases such as acute angle-closure glaucoma, retinal artery occlusion, and amaurosis fugax.<sup>3</sup> It can irreversibly damage the retina, causing visual impairment and blindness. Immediate mechanisms of I/R injury involve the formation of reactive oxygen species (ROS),<sup>4</sup>

which has been considered to contribute to the pathogenesis of many neurodegenerative diseases, including glaucomatous neurodegeneration.<sup>5</sup> Endogenous antioxidant enzymes and organic free radical scavengers can retard or prevent neuronal damages of retinal I/R injury in many animal models.<sup>6-13</sup> One highly reactive ROS, hydroxyl radical ( $\cdot\text{OH}$ ), is generated during the early phase of reperfusion after ischemia and a major cause of retinal injury.<sup>14-16</sup>  $\cdot\text{OH}$  attacks lipids, proteins and nucleic acids causing irreversible cellular damage.

In the past two decades, much attention has been focused on the use of several pharmaceutical gaseous molecules to attenuate oxidative stress.<sup>17</sup> A variety of gas delivery systems are used and under development for safe and effective administration of medical gases. We have reported that  $\text{H}_2$  selectively reduces  $\text{OH}$  and peroxynitrite without affecting other oxygen-derived free radicals.<sup>18</sup> Inhalation of  $\text{H}_2$  gas has been demonstrated to limit the infarct volume of the brain, heart, and liver by reducing I/R injury<sup>18-21</sup> and can ameliorate intestinal transplant injury.<sup>22</sup> Moreover, the consumption of water with dissolved  $\text{H}_2$  to a saturated level prevents stress-induced cognitive decline and 6-hydroxydopamine-induced nigrostriatal degeneration.<sup>23,24</sup> One clinical trial demonstrated a decrease in low-density lipoprotein after drinking  $\text{H}_2$ -loaded water.<sup>25</sup>  $\text{H}_2$  has the potential to easily diffuse into organs and no known toxic effects on the human body.<sup>18</sup>

We have therefore developed a simple and effective method to deliver  $\text{H}_2$  into lesions. The method is  $\text{H}_2$ -loaded eye drops, which are convenient, compared with the inhalation of  $\text{H}_2$  gas, for the treatment of eye diseases. In this article, we demonstrate that the continuous administration of  $\text{H}_2$ -loaded eye drops immediately increases  $\text{H}_2$  concentration in the vitreous body and prevents I/R-induced oxidative stress, leading to a decrease in apoptotic cell death in the retina and a decrease in retinal thinning with glial responses.

## Methods

### Administration of $\text{H}_2$ and Measurement of its Concentration

$\text{H}_2$ -loaded eye drops were prepared by bubbling  $\text{H}_2$  gas (flow rate: 1 L/min) through 400 mL of normal saline solution with stirring for 10 minutes to a saturated level (Fig. 1A), and then stored in an aluminum foil bag (Fig. 1B; Hosokawa Yoko, Tokyo, Japan) with no dead volume. The concentration of  $\text{H}_2$  in the bag slowly decreased with a half-life of approximately 3 months. Freshly prepared  $\text{H}_2$ -loaded eye drops were administered to the ocular surface continuously (4 mL/min) with a dropper connected to the aluminum foil bag during the ischemia and/or reperfusion periods. The  $\text{H}_2$  dissolved in saline solution was measured by using a needle-type  $\text{H}_2$  sensor (Unisense, Aarhus N, Denmark). The  $\text{H}_2$  concentration on the ocular surface was measured by touching the sensor to the surface.  $\text{H}_2$  concentration was measured in the vitreous body by inserting the sensor into the vitreous body through the sclera.

To investigate the effect of  $\text{H}_2$ -loaded eye drops on retinal I/R injury, we applied them using four different time courses (see Fig. 4A): duration F, eye drops with and without  $\text{H}_2$  were applied during an entire 90-minute process (60 minutes of ischemia followed by 30 minutes of reperfusion); duration I, eye drops with  $\text{H}_2$  were applied only during ischemia; duration R, eye drops with  $\text{H}_2$  were applied only after reperfusion; and duration I/R, eye drops with  $\text{H}_2$  were applied for 10 minutes before and 30 minutes after reperfusion.

### Induction of I/R Injury

Retinal I/R injury was induced essentially as described previously.<sup>2,26</sup> Seven-week-old male Sprague–Dawley rats weighing 200 to 250 g were anesthetized with an intraperitoneal injection of pentobarbital (100 mg/kg), and the pupils were dilated with topical phenylephrine hydrochloride and tropicamide. After topical application of 0.4% oxybuprocaine hydrochloride, the anterior chamber was cannulated with a 30-gauge infusion needle connected to a normal saline reservoir. The IOP was raised to 110 mm Hg for 60 minutes by elevating the saline reservoir. Body temperature was maintained at  $37.0 \pm 0.5$  °C with a rectal thermometer probe and a heating pad during the experimental period. Retinal ischemia was confirmed by whitening of the iris and fundus. After 60 minutes of ischemia, the needle was withdrawn from the anterior chamber and the intraocular pressure was normalized. The animals were euthanatized with an overdose of anesthesia after reperfusion, and the eyes were immediately enucleated. All animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The studies were approved by the Animal Care and Use

Committee of Nippon Medical School. All experiments were performed by examiners blinded to the genotypes or treatments of the rat.

#### Detection of OH

The procedure for the measurement of accumulated OH in the eye is similar to that previously described with modifications.<sup>27</sup> We used 2-[6-(4'-hydroxy)phenoxy-3*H*-xanthen-3-on-9-yl] benzoate (HPF; Daiichi Pure Chemicals, Tokyo, Japan), which detects highly reactive ROS including OH, as a fluorescence probe.<sup>28</sup> HPF (4  $\mu$ L, 1 mM) was given intravitreally just before the induction of ischemia. Rats were killed after 60 minutes of ischemia followed by 15 minutes of reperfusion. Retinas were quickly removed and flat mounted without fixation. The fluorescence images were acquired by using a laser scanning confocal microscope. The acquired images were analyzed by quantitative comparisons of the relative fluorescence intensity of retinas between groups (NIH Image software, developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available at <http://rsb.info.nih.gov/ij/index.html>).

#### Histopathologic and Morphometric Study

Eyes were enucleated 7 days after reperfusion and fixed in 1% glutaraldehyde and 4% paraformaldehyde (PFA) in 0.1 M phosphate-buffered saline (PBS) for 30 minutes, and the anterior segments were removed. Corneas and lenses were discarded. The entire eye cups were further fixed in the same solution overnight and then transferred to 30% sucrose for cryoprotection. Cryosections (10  $\mu$ m thick) were cut along the vertical meridian of the eye, passing through the optic nerve head, and were stained with hematoxylin and eosin (H&E). Retinal damage was assessed by measuring the thickness of the retina.<sup>1</sup> The thickness is defined as the total width between the inner limiting membrane to the interface of the outer plexiform layer and the outer nuclear layer. These measurements were made at a distance within 1 to 2 mm from the optic disc using a light microscope. The value was averaged from four measurements in the temporal and nasal hemispheres of three different sections.

#### TUNEL Assay and Immunohistochemical Staining

One day or 7 days after reperfusion, the eyes were immediately enucleated. For TUNEL assay and the staining of reactive gliosis markers, they were fixed in 4% PFA, and for staining of oxidative stress markers they were fixed in Bouin's fluid for 30 minutes. Next, the anterior segments were removed and the corneas and lenses were discarded. For the TUNEL assay and for the staining of reactive gliosis markers, the obtained entire eye cups were further fixed in the same solution overnight. For the staining of oxidative stress markers, they were further fixed in the same solution for 2 hours. After cryoprotection with 30% sucrose, cryosections (10  $\mu$ m thick) were cut along the vertical meridian of the eye, passing through the optic nerve head. TUNEL staining was performed with an apoptosis detection kit according to the supplier's instructions (Chemicon, Norcross, GA).<sup>29</sup> The numbers of TUNEL-positive cells in the retina were counted at a final magnification  $\times 200$  for each section using a light microscope.

For the immunostaining of oxidative stress markers, 4-hydroxynonenal (4-HNE) and 8-hydroxy-2-deoxyguanosine (8-OHdG),<sup>30,31</sup> cryosections were postfixed in acetone and stained using the ABC kit according to the supplier's instructions (Vector Laboratories, Burlingame, CA).<sup>18</sup> Sections were incubated with the following primary antibodies: mouse monoclonal anti-4-HNE (1:400; JaICA, Shizuoka, Japan) and mouse monoclonal anti-8-OHdG (1:20; JaICA), in a blocking buffer for 1 hour at 4 °C. The stained sections were further counterstained for nuclei with methyl green (0.5%). A light microscope was used to count the number of 4-HNE- and 8-OHdG-positive cells in each section of the retina at a final magnification of  $\times 200$ .

For immunofluorescent staining of microglia and macroglia (astrocytes and Müller cells), cryosections were incubated with the following primary antibodies: rabbit polyclonal anti-Iba1<sup>32</sup> (1:100; Wako, Osaka, Japan) or rabbit polyclonal anti-gial fibrillary acidic proteins (GFAP; 1:500; DAKO, Glostrup, Denmark) in blocking buffer for 1 hour at room temperature. After they were washed twice with PBS, the sections were incubated with fluorescein isothiocyanate (FITC)-conjugated secondary antibody (1:100; Invitrogen, Carlsbad, CA) for 30 minutes and further counterstained for nuclei with propidium iodide for 10 minutes. A laser scanning confocal microscope (FV300; Olympus, Tokyo, Japan) was used to count the number of Iba1-positive cells in each section of the retina at a final magnification of  $\times 200$ .

### Statistical Analysis


All data are presented as the mean  $\pm$  SD. For single comparisons, we performed an unpaired two-tailed Student's *t*-test. For multiple comparisons, we used an analysis of variance (ANOVA) followed by the Fisher least-significant difference (LSD) test (StatView; SAS Institute, Cary, NC).  $P < 0.05$  was considered statistically significant.

### Results

#### Effect of H<sub>2</sub>-Loaded Eye Drops on H<sub>2</sub> Concentration in the Vitreous Body and the Accumulation of OH during Retinal I/R

We prepared an H<sub>2</sub>-saturated normal saline solution (0.8 mM, pH 7.2; H<sub>2</sub>-loaded eye drops) and packed it into an aluminum foil bag to prevent a decrease in H<sub>2</sub> concentration. A dropper connected to the bag was held close to the rat's eye, and drops were applied to the ocular surface. The time-course of changes in H<sub>2</sub> levels was monitored with a needle-shaped hydrogen sensor electrode inserted through the sclera to the vitreous body. When H<sub>2</sub>-loaded eye drops were administered continuously, approximately 0.5 mM H<sub>2</sub> was detected on the ocular surface (Fig. 1C). Two minutes after the start of administration, H<sub>2</sub> concentration in the vitreous body started to increase and reached a maximum level after 15 minutes (Fig. 1D). At that time, the H<sub>2</sub> concentration accounted for approximately 20% (0.16 mM) of the H<sub>2</sub>-loaded eye drops. Immediately after administration of the H<sub>2</sub>-loaded eye drops ceased, the H<sub>2</sub> concentration in the vitreous body was observed to gradually decrease and then completely disappear after 15 minutes (Fig. 1D). The maximum observed concentration of H<sub>2</sub> in the vitreous body was approximately one third of that observed on the ocular surface (Fig. 1E).


Figure 1.



H<sub>2</sub>-loaded eye drops increased intravitreal H<sub>2</sub>. (A) H<sub>2</sub>-loaded eye drops were prepared by bubbling H<sub>2</sub> gas (*solid thick line*, flow rate: 1 L/min) through 400 mL of normal saline solution. After the bubbling was stopped, the H<sub>2</sub> concentration was gradually decreased by stirring and reached <1% within 90 minutes. (B) H<sub>2</sub>-loaded eye drops were stored in an aluminum foil bag and administered to the ocular surface with a dropper. Scale bar, 4 cm. The concentrations of H<sub>2</sub> on the ocular surface (C) and in the vitreous body (D) were monitored with a needle-type H<sub>2</sub> sensor. *Solid thick line*: application times of H<sub>2</sub>-loaded eye drops (4 mL/min). (E) Summary data showing H<sub>2</sub> concentration on the ocular surface (OS;  $n = 3$ ) and in the vitreous body (VB;  $n = 3$ ). Data represents the mean  $\pm$  SD.

To verify that the diffused H<sub>2</sub> protects against OH during retinal I/R, we assessed the accumulation of OH by the fluorescence signal emitted by the oxidized form of HPF.<sup>28</sup> We produced retinal ischemia in rats by increasing IOP with an infusion needle connected to a saline bag. Just before the induction of ischemia, 4 μL of 1 mM HPF was given intravitreally, followed by 60 minutes of ischemia. Fifteen minutes after reperfusion, the retinas were flatmounted and imaged in their entirety using a laser confocal-scanning microscope (Fig. 2A). The retinal HPF-fluorescence in the H<sub>2</sub>-loaded eye drop-treated group was significantly less than that in the vehicle-treated group (Fig. 2B).

Figure 2.




H<sub>2</sub>-loaded eye drops reduced hydroxyl radicals in the retina. HPF was given intravitreally just before the induction of ischemia. After I/R, the retinas were quickly removed and flat mounted. (A) Representative fluorescent images were obtained with a laser scanning confocal microscope. (B) HPF fluorescence was quantified from the entire retina of each independent experiment. \**P* < 0.01. Data represent the mean ± SD. Scale bar, 200 μm.

#### Effect of H<sub>2</sub>-Loaded Eye Drops on the Number of Apoptotic and Oxidative Stress Marker-Positive Cells

To determine whether the administration of H<sub>2</sub>-loaded eye drops protects against retinal I/R injury, eye drops with and without H<sub>2</sub> were applied during the entire 90 minutes process (60 minutes of ischemia followed by 30 minutes of reperfusion). One day after I/R injury, a remarkable increase in the number of apoptotic cells (TUNEL-positive cells) was observed in both the inner and the outer nuclear layers of vehicle-treated retinas (Fig. 3A); however, the administration of H<sub>2</sub>-loaded eye drops resulted in a significant decrease (approximately 77%, *P* < 0.0001) of TUNEL-positive cells (Figs. 3A, 3B), indicating that H<sub>2</sub>-loaded eye drops had potent antiapoptotic activity. We speculate that the decreased apoptotic cell death reflects the H<sub>2</sub>-dependent reduction of oxidative stress, which was mainly promoted by OH.

Figure 3.






H<sub>2</sub>-loaded eye drops reduced apoptotic cell death and oxidative stress. One day after I/R, the eyes were immediately enucleated and fixed for TUNEL assay (**A, B**) and staining with antibodies against oxidative stress markers 4-HNE (**C, D**) and 8-OHdG (**E, F**). Images of representative slices (**A, C, E**) and the number of positive cells per field of view (FOV) (**B, D, F**) in normal retina (N) and the I/R-injured retinas treated with the vehicle (H<sub>2</sub> -) or the H<sub>2</sub>-loaded eye drops (H<sub>2</sub> +) are shown (*n* = 5 animals per group). \*\**P* < 0.001. \*\*\**P* < 0.0001. Data represent the mean ± SD. Scale bar, 30 μm.

We then examined the levels of two oxidative stress markers, 4-HNE and 8-OHdG, in the vehicle-treated and the H<sub>2</sub>-loaded eye drop-treated eyes by immunohistochemical staining with each specific antibody.<sup>30,31</sup> As expected,<sup>9</sup> one day after I/R injury, the number of 4-HNE- and 8-OHdG-positive cells increased dramatically in the retina (Figs. 3C, 3E, respectively). However, eyes that had been treated with H<sub>2</sub>-loaded eye drops exhibited significantly fewer 4-HNE and 8-OHdG-positive cells compared with the vehicle-treated retinas (Figs. 3C–F), supporting our formulated hypothesis.

#### Effect of H<sub>2</sub>-Loaded Eye Drops on Histopathologic and Morphometric Changes

To further evaluate the protective effect of H<sub>2</sub>-loaded eye drops, we observed histopathologic and morphometric changes 7 days after retinal I/R injury. First, eye drops with and without H<sub>2</sub> were applied during the entire 90-minute process (duration F in Fig. 4A). Histopathologic changes of the retina at 7 days after I/R injury are depicted in Figure 4B. The H<sub>2</sub>-loaded eye drop-treated group showed a nearly normal structure with a thicker retina; however, the H<sub>2</sub>-free (vehicle) eye drops-treated group exhibited a marked thinning and atrophy of the retina. Quantitative morphometry of retinal thickness was used to estimate the effect of H<sub>2</sub> (Fig. 4C). The thickness in the I/R-injured retina treated with the H<sub>2</sub>-loaded eye drops ( $102.6 \pm 3.8 \mu\text{m}$ ) increased significantly compared with the retina treated with the vehicle ( $66.9 \pm 7.8 \mu\text{m}$ , *P* < 0.0001). In normal retina from untreated animals, the mean thickness of the retina was  $117.0 \pm 4.5 \mu\text{m}$ , indicating that the H<sub>2</sub>-loaded eye drops improved the recovery of retinal thickness by >70%.

Figure 4.




H<sub>2</sub>-loaded eye drops prevented retinal degeneration caused by I/R. One week after I/R injury, the retinas were sliced and stained with H&E. (A) Schematic of the experiment, with four different durations of H<sub>2</sub>-loaded eye drops administration. (B) Images of representative slices of normal retinas, I/R-injured retinas treated with vehicle, and retinas treated with H<sub>2</sub>-loaded eye drops during the entire 90-minute process (60 minutes of ischemia followed by 30 minutes of reperfusion) are shown. Scale bar, 50 μm. (C) Retinal thicknesses for different durations of H<sub>2</sub>-loaded eye drops (100%) administration. \*\*\**P* < 0.0001 compared with I/R-injured retina treated with the vehicle (H<sub>2</sub> -). (D) Retinal thicknesses at different concentrations of H<sub>2</sub> in eye drops. The retinas were treated with H<sub>2</sub>-loaded eye drops during the entire process (duration F). \**P* < 0.01, \*\**P* < 0.001, \*\*\**P* < 0.0001 compared with I/R-injured retina treated with 0% H<sub>2</sub>. Histograms represent the mean ± SD.

To investigate the effect of different durations of H<sub>2</sub>-loaded eye drop administration, we applied H<sub>2</sub>-loaded eye drops using three different time courses (Fig. 4A) and observed that the H<sub>2</sub>-loaded eye drops exerted their effect only when H<sub>2</sub> was already inside the eyeball at the onset of reperfusion (Fig. 4C). There were no significant differences in retinal thickness between groups treated with H<sub>2</sub>-loaded eye drops only after reperfusion (duration R; 75.4 ± 10.4 μm) and treated with vehicle (*P* = 0.06). However, the retina that was treated with H<sub>2</sub>-loaded eye drops only during ischemia (duration I; 91.6 ± 7.5 μm) was still significantly thicker than that treated with the vehicle (*P* < 0.01). We next administered H<sub>2</sub>-loaded eye drops for 10 minutes before and 30 minutes after reperfusion (duration I/R) and observed that the administration schedule was sufficient to suppress the reduction of retinal thickness (duration I/R; 96.6 ± 4.4 μm; *P* < 0.001 vs. vehicle). Furthermore, we applied eye drops diluted to 25%, 50%, and 75% of the normal H<sub>2</sub>-loaded eye drops during the entire 90-minute process and observed that H<sub>2</sub>-loaded eye drops suppressed the reduction of retinal thickness in a dose-dependent manner (Fig. 4D). It is notable that the 25%-diluted H<sub>2</sub>-loaded eye drops were still effective.

#### Effect of H<sub>2</sub>-Loaded Eye Drops on Glial Activation

Considering the critical role of increasing glial activation in the pathogenic progression of retinal damage, we investigated the immunohistochemical changes of the Iba1<sup>32</sup> and GFAP<sup>33</sup> at 7 days after retinal I/R injury with and without H<sub>2</sub> treatment. Iba1 is specifically expressed by microglia/macrophages.<sup>34</sup> A small number of Iba1-positive cells was observed in normal retinas, whereas an increasing number of Iba1-positive cells was observed in I/R-injured retinas. At that time, H<sub>2</sub>-loaded eye drops were observed to inhibit the activation of microglia (Figs. 5A, 5B), indicating that the ongoing neurodegeneration, which activated microglia, was repressed by H<sub>2</sub>. In addition, H<sub>2</sub>-loaded eye drops repressed the increase in GFAP immunoreactivity in I/R-injured retinas. The only GFAP-positive cells in normal retina are astrocytes, whereas in the injured retinas, Müller cells, the specific glial cells in the retina, react with anti-GFAP antibody across the retinal layers.<sup>33</sup> In vehicle-treated retinas, GFAP was quite prominent in the Müller cells across the retinal layers and was also strongly present in the astrocytes of the nerve fiber layers, when compared with the H<sub>2</sub>-loaded eye drop-treated retinas (Fig. 5C).

Figure 5.



H<sub>2</sub>-loaded eye drops prevented glial activation caused by I/R in the retina. One week after I/R injury, the retinas were sliced, stained with antibodies to Iba1 (a marker for microglia/macrophages, *green*) (A, B) and GFAP (a marker for Müller cells and astrocytes, *green*) (C), and further counterstained for nuclei with propidium iodide (*red*). Images of representative slices (A, C) and the number of positive cells per field of view (FOV) (B) in normal retina (N) and I/R-injured retinas treated with the vehicle (H<sub>2</sub> -) or H<sub>2</sub>-loaded eye drops (H<sub>2</sub> +) are shown ( $n = 5$  animals per group). \* $P < 0.01$ . Data represent the mean  $\pm$  SD. Scale bar, 50  $\mu$ m.

#### Discussion

H<sub>2</sub>-loaded eye drops have a strong protective effect against retinal I/R injury. Previous studies have demonstrated that antioxidants can decrease retinal injury<sup>6-15</sup>; however, because antioxidants are difficult to deliver into the vitreous body by topical administration, they were injected into either the eye or the peritoneal cavity. Thus, easily applicable antioxidative reagents without significant side effects are strongly desirable. H<sub>2</sub> is an antioxidant that can easily diffuse into the body. We have observed that H<sub>2</sub> diffuses into the organelles, including mitochondria and the nucleus, of cultured cells.<sup>18</sup> These properties prompted us to attempt the administration of H<sub>2</sub>-loaded eye drops for retinal diseases. This is the first report that H<sub>2</sub> can immediately penetrate the vitreous body after the administration of H<sub>2</sub>-loaded eye drops, thereby directly reducing a toxic ROS,  $\cdot$ OH, which is produced during I/R. This effectively protects the retina from I/R injury.

Although the sources and mechanisms of ROS generation during I/R by transiently raised IOP are not clearly understood, ROS kills neurons in the ganglion cell layer, inner nuclear layer, and outer nuclear layer mainly by apoptosis.<sup>5,9,35</sup> Ophir et al.<sup>14,15</sup> demonstrated that a burst of OH occurs in the cat retina during the early reperfusion phase (5 minutes of reperfusion). Thus, we assessed OH after 15 minutes of reperfusion with HPF fluorescence and found that the accumulation of ·OH was reduced by H<sub>2</sub>-loaded eye drops in the I/R-injured retina, indicating that H<sub>2</sub> directly reduced OH and decreased subsequent oxidative stress. Indeed, 1 day after reperfusion, H<sub>2</sub>-loaded eye drops dramatically decreased 4-HNE-, 8-OHdG-, and TUNEL-positive cells indicating that H<sub>2</sub> protected lipids from peroxidation and DNA from oxidation and reduced subsequent retinal cell death (detected as apoptosis) after I/R injury.

Neurodegeneration was obvious at 7 days after retinal I/R injury. Previous studies on retinal damage 7 days after I/R injury have shown that the thinning of the retina was evident both morphologically and morphometrically.<sup>1,26,36,37</sup> In the present study, H<sub>2</sub>-loaded eye drops clearly suppressed the thinning of the retina. However, when H<sub>2</sub>-loaded eye drops were applied after the onset of reperfusion (duration R), they did not protect from retinal damage (Fig. 4). As shown in Figure 1, H<sub>2</sub> concentration in the vitreous body gradually increased after 2 minutes and reached its maximum level after 15 minutes. Immediately after H<sub>2</sub>-loaded eye drop administration was stopped, the H<sub>2</sub> level gradually decreased and then completely disappeared after 15 minutes. Thus, H<sub>2</sub> applied after the onset of reperfusion could not reach a level sufficient to inhibit the accumulation of OH in the early reperfusion phase, whereas H<sub>2</sub> applied before or during reperfusion (duration I or I/R) had a high enough H<sub>2</sub> level.

Microglia, Müller cells, and most likely astrocytes respond within hours to elevation of IOP in the retina.

<sup>38</sup> Heterogeneous populations of microglia/macrophages are observed in the normal retina and activated early after I/R injury.<sup>39</sup> Dying neurons are phagocytosed by them. The long duration of ROS production (up to 48 hours after I/R) may be explained partly by the infiltration of microglia/macrophages into the site of inflammation.<sup>9</sup> The presence of GFAP in a glial cell is considered a marker for reactive gliosis, which is not neuroprotective, but rather promotes neurodegeneration.<sup>40</sup> H<sub>2</sub>-loaded eye drops reduced the number of reactive glia, indicating that H<sub>2</sub>-loaded eye drops during I/R were sufficient to suppress harmful gliosis after I/R injury and recover the thickness of the retina.

In conclusion, this study demonstrates that the topical application of H<sub>2</sub> can be a useful antioxidant to protect against retinal I/R injury by direct H<sub>2</sub> diffusion into the retina. Accordingly, this neuroprotective antioxidant could offer a new therapeutic strategy to the clinical setting to reduce retinal damage in acute glaucoma and acute retinal vascular occlusion.

#### Footnotes

Supported in part by Ministry of Education, Culture, Sports, Science, and Technology of Japan Grants-in-Aid 19659331 (SO) and 20500345 (IO).

Disclosure: **H. Oharazawa**, None; **T. Igarashi**, None; **T. Yokota**, None; **H. Fujii**, None; **H. Suzuki**, None; **M. Machide**, None; **H. Takahashi**, None; **S. Ohta**, None; **I. Ohsawa**, None

#### References

1. Hughes WF. Quantitation of ischemic damage in the rat retina. *Exp Eye Res.* 1991; 53: 573–582. [CrossRef] [PubMed]
2. Kuroiwa S Katai N Shibuki H. Expression of cell cycle-related genes in dying cells in retinal ischemic injury. *Invest Ophthalmol Vis Sci.* 1998; 39: 610–617. [PubMed]
3. Osborne NN Casson RJ Wood JPM Chidlow G Graham M Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. *Prog Retina Eye Res.* 2004; 23: 91–147. [CrossRef]
4. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. *N Engl J Med.* 1985; 312: 159–163. [CrossRef] [PubMed]
5. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. *Prog Retinal Eye Res.* 2006; 25: 490–513. [CrossRef]
6. Szabo ME Droy-Lefaix MT Doly M Carré C Braquet P. Ischemia and reperfusion-induced histologic changes in the rat retina. *Invest Ophthalmol Vis Sci.* 1991; 32: 1471–1478. [PubMed]

7. Muller A Pietri S Villain M Frejaville C Bonne C Culcasi M. Free radicals in rabbit retina under ocular hyperpressure and functional consequences. *Exp Eye Res.* 1997; 64: 637–643. [CrossRef] [PubMed]
8. Shibuki H Katai N Kuroiwa S Kurokawa T Yodoi J Yoshimura N. Protective effect of adult T-cell leukemia-derived factor on retinal ischemia-reperfusion injury in the rat. *Invest Ophthalmol Vis Sci.* 1998; 39: 1470–1477. [PubMed]
9. Shibuki H Katai N Yodoi J Uchida K Yoshimura N. Lipid peroxidation and peroxynitrite in retinal ischemia-reperfusion injury. *Invest Ophthalmol Vis Sci.* 2000; 41: 3607–3614. [PubMed]
10. Hirooka K Miyamoto O Jinming P. Neuroprotective effects of D-allose against retinal ischemia-reperfusion injury. *Invest Ophthalmol Vis Sci.* 2006; 47: 1653–1657. [CrossRef] [PubMed]
11. Zhang B Safa R Rusciano D Osborne NN. Epigallocatechin gallate, an active ingredient from green tea, attenuates damaging influences to the retina caused by ischemia/reperfusion. *Brain Res.* 2007; 1159: 40–53. [CrossRef] [PubMed]
12. Peachey NS Green DJ Ripps H. Ocular ischemia and the effects of allopurinol on functional recovery in the retina of the arterially perfused cat eye. *Invest Ophthalmol Vis Sci.* 1993; 34: 58–65. [PubMed]
13. Li S Fu Z Ma H. Effect of lutein on retinal neurons and oxidative stress in a model of acute retinal ischemia/reperfusion. *Invest Ophthalmol Vis Sci.* 2009; 50: 836–843. [CrossRef] [PubMed]
14. Ophir A Berenshtein E Kitrossky N. Hydroxyl radical generation in the cat retina during reperfusion following ischemia. *Exp Eye Res.* 1993; 57: 351–357. [CrossRef] [PubMed]
15. Ophir A Berenshtein E Kitrossky N Averbukh E. Protection of the transiently ischemic cat retina by zinc-desferrioxamine. *Invest Ophthalmol Vis Sci.* 1994; 35: 1212–1222. [PubMed]
16. Song Y Gong Y Xie Z Li C Gu Q Wu X. Edaravone (MCI-186), a free radical scavenger, attenuates retinal ischemia/reperfusion injury in rats. *Acta Pharmacol Sin.* 2008; 29: 823–828. [CrossRef] [PubMed]
17. Nakao A Sugimoto R Billiar TR McCurry KR. Therapeutic antioxidant medical gas. *J Clin Biochem Nutr.* 2009; 44: 1–13. [CrossRef] [PubMed]
18. Ohsawa I Ishikawa M Takahashi K. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med.* 2007; 13: 688–694. [CrossRef] [PubMed]
19. Cai J Kang Z Liu K. Neuroprotective effects of hydrogen saline in neonatal hypoxia-ischemia rat model. *Brain Res.* 2009; 1256: 129–137. [CrossRef] [PubMed]
20. Hayashida K Sano M Ohsawa I. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. *Biochem Biophys Res Commun.* 2008; 373: 30–35. [CrossRef] [PubMed]
21. Fukuda K Asoh S Ishikawa M Yamamoto Y Ohsawa I Ohta S. Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. *Biochem Biophys Res Commun.* 2007; 361: 670–674. [CrossRef] [PubMed]
22. Buchholz BM Kaczorowski DJ Suquimoto R. Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. *Am J Transplant.* 2008; 8: 2015–2024. [CrossRef] [PubMed]
23. Nagata K Nakashima-Kamimura N Mikami T Ohsawa I Ohta S. Consumption of molecular hydrogen prevents the stress-induced impairments in hippocampus-dependent learning tasks during chronic physical restraint in mice. *Neuropsychopharmacology.* 2009; 34: 501–508. [CrossRef] [PubMed]
24. Fu Y Ito M Fujita Y. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease. *Neurosci Lett.* 2009; 453: 81–85. [CrossRef] [PubMed]
25. Kajiyama S Hasegawa G Asano M. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. *Nutr Res.* 2008; 28: 137–143. [CrossRef] [PubMed]
26. Lam TT. The effect of 3-aminobenzamide, an inhibitor of poly-ADP-ribose polymerase, on ischemia/reperfusion damage in rat retina. *Res Commun Mol Pathol Pharmacol.* 1997; 95: 241–252. [PubMed]
27. Tomizawa S Imai H Tsukada S. The detection and quantification of highly reactive oxygen species using the novel HPF fluorescence probe in a rat model of focal cerebral ischemia. *Neurosci Res.* 2005; 53: 304–313. [CrossRef] [PubMed]
28. Setsukinai K Urano Y Kakinuma K Majima HJ Nagano T. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. *J Biol Chem.* 2003; 278: 3170–3175. [CrossRef] [PubMed]
29. Gavrieli Y Sherman Y Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol.* 1992; 119: 493–501. [CrossRef] [PubMed]

30. Petersen DR Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. *Free Radic Biol Med.* 2004; 37: 937–945. [CrossRef] [PubMed]
31. Kamiya H. Mutagenicities of 8-hydroxyguanine and 2-hydroxyadenine produced by reactive oxygen species. *Biol Pharm Bull.* 2004; 27: 475–479. [CrossRef] [PubMed]
32. Imai Y Ibata I Ito D Ohsawa K Kohsaka S. A novel gene iba 1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. *Biochem Biophys Res Commun.* 1996; 224: 855–862. [CrossRef] [PubMed]
33. Block F Grommes C Kosinski C Schmidt W Schwarz M. Retinal ischemia induced by the intraluminal structure method in rats. *Neurosci Lett.* 1997; 232: 45–48. [CrossRef] [PubMed]
34. Sasaki Y Ohsawa K Kanazawa H. Iba1 is an actin-cross-linking protein in macrophages/microglia. *Biochem Biophys Res Commun.* 2001; 286: 292–297. [CrossRef]
35. Bonne C Muller A Villain M. Free radicals in retinal ischemia. *Gen Pharmac.* 1998; 30: 275–280. [CrossRef]
36. Takahashi K Lam TT Edward DP Buchi ER Tso MOM. Protective effects of flunarizine on ischemic injury in the rat retina. *Arch Ophthalmol.* 1992; 110: 862–870. [CrossRef] [PubMed]
37. Junk AK Mammis A Savitz SI . Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. *Proc Natl Acad Sci USA.* 2002; 99: 10659–10664. [CrossRef] [PubMed]
38. Wang X Tay SS Ng YK. An immunohistochemical study of neuronal and glial cell reactions in retinæ of rats with experimental glaucoma. *Exp Brain Res.* 2000; 132: 476–484. [CrossRef] [PubMed]
39. Zhang C Lam TT Tso MO. Heterogeneous populations of microglia/macrophages in the retina and their activation after retinal ischemia and reperfusion injury. *Exp Eye Res.* 2005; 81: 700–709. [CrossRef] [PubMed]
40. Kim K Ju W Neufeld AH. Neuronal susceptibility to damage: comparison of the retinas of young, old and old/caloric restricted rats before and after transient ischemia. *Neurobiol Aging.* 2004; 25: 491–500. [CrossRef] [PubMed]